[at Motley Fool] – With Gilead (GILD), Johnson and Johnson (JNJ), AbbVie (ABBV), Bristol-Myers (BMY), and Merck (MRK) rushing to get next generation hepatitis C drugs to market, here are the facts you . . . → Read More: Company Update: Gilead Sciences Inc. (NASDAQ:GILD) – What Everybody Ought to Know About Gilead and Johnson’s New Hepatitis C Drugs Similar posts: AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review Boeing’s Double Top: Will the company continue to soar?